Exemestane following tamoxifen in postmenopausal women with primary breast cancer

[1] Baum M, 2003, Cancer, V98, P1802

[2] The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months [J]. Breast Cancer Research and Treatment, 2003, 77 (3) : 295 - 295

[3] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1081 - 1092

[4] The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats [J]. BONE, 2004, 34 (03) : 384 - 392

[5] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) : 1793 - 1802

[6] Howell A, 2003, BREAST CANCER RES TR, V82, pS27

[7] Nabholtz JMA, 2001, J CLIN ONCOL, V19, P2107, DOI 10.1200/JCO.2001.19.7.2107

[1] Baum M, 2003, Cancer, V98, P1802

[2] The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months [J]. Breast Cancer Research and Treatment, 2003, 77 (3) : 295 - 295

[3] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1081 - 1092

[4] The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats [J]. BONE, 2004, 34 (03) : 384 - 392

[5] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) : 1793 - 1802

[6] Howell A, 2003, BREAST CANCER RES TR, V82, pS27

[7] Nabholtz JMA, 2001, J CLIN ONCOL, V19, P2107, DOI 10.1200/JCO.2001.19.7.2107